Genomic analysis of the cervical carcinoma cells treated with the anti-inflammatory protein annexin A1

• Grant number: 12/08320-1
• Support Opportunities: Regular Research Grants
• Start date: November 01, 2012
• End date: October 31, 2014
• Field of knowledge: Biological Sciences - Genetics - Human and Medical Genetics
• Principal Investigator: Flávia Cristina Rodrigues Lisoni
• Grantee: Flávia Cristina Rodrigues Lisoni
• Host Institution: Instituto de Biociências, Letras e Ciências Exatas (IBILCE). Universidade Estadual Paulista (UNESP). Campus de São José do Rio Preto. São José do Rio Preto , SP, Brazil
• Associated researchers: Sonia Maria Oliani

Abstract

The cervical cancer is the second type of more frequent cancer in women world-wide, being the fourth cause of death for cancer in developing countries. Cervical carcinogenesis is related with genetic alterations, infection for Human PapilomaVirus (HPV), angiogenesis and inflammatory processes. The idea of that the inflammation is involved in tumorigenesis is supported by the comment of that the cancer appears frequently in areas of chronic inflammation. On the other hand, the inflammatory reply is controlled for the action of anti-inflammatory mediators, who act to keep the homeostasis of the immunological reply to prevent the tecidual injury. Among these mediators we detach the annexin A1 (ANXA1), protein of 37 kDa, that is express for the tumoral cells and acts as modulating of the inflammatory process. However, the molecular mechanisms for which the ANXA1 modulates the cellular answers in the inflammatory processes are not yet completely determined. The available data suggest that this protein family can have, beyond its important role in the inflammatory process, a significant involvement in the cancer, through signaling cascades that include genes related with the cellular cycle, the differentiation and apoptosis. Ahead of these considerations, we will investigate, in vitro, the influence of this anti-inflammatory one in the SiHa cells on the morphology, cellular proliferation and localization and in the proteic and gene expression, observing as the ANXA1 modulates the expression of these genes and as these alterations can participate of the tumorigenic process. For this, the cell line SiHa will be used (derived from the cervical squamous cell carcinoma), treated with ANXA1 for 1, 2, 4, 24, 48 and 72 hours. Specifically, it will be investigated the effect of this addition in the gene expression, by rapid subtractive hybridization (RaSH) and the differentially expressed genes distinguishing, will be validated by techniques of quantitative PCR, then, will be investigated the ways of cellular signaling, of which the ANXA1 participates, important for the tumorigenic process. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

CARDIN, LAILA TONIOL; SONEHARA, NATHALIA MARTINS; OLIVEIRA MIMURA, KALLYNE KIOKO; DINARTE DOS SANTOS, ANEMARI RAMOS; DA SILVA JUNIOR, WILSON ARAUJO; SOBRAL, LAYS MARTIN; LEOPOLDINO, ANDREIA MACHADO; DA CUNHA, BIANCA RODRIGUES; TAJARA, ELOIZA H.; OLIANI, SONIA MARIA; et al. ANXA1(Ac2-26) peptide, a possible therapeutic approach in inflammatory ocular diseases. Gene, v. 614, p. 26-36, MAY 30 2017. (12/08320-1, 16/02012-4, 13/24083-2)

PRATES, JANESLY; FRANCO-SALLA, GABRIELA BUENO; DINARTE DOS SANTOS, ANEMARI RAMOS; DA SILVA, JR., WILSON ARAUJO; DA CUNHA, BIANCA RODRIGUES; TAJARA, ELOIZA HELENA; OLIANI, SONIA MARIA; RODRIGUES-LISONI, FLAVIA CRISTINA. ANXA1(Ac2-26) peptide reduces ID1 expression in cervical carcinoma cultures. Gene, v. 570, n. 2, p. 248-254, OCT 10 2015. (12/08320-1, 12/08177-4)